HBE1 and hepatocellular carcinoma: HBcrAg can predict hepatitis B e antigen (HBeAg) seroconversion to antibody (anti-HBe) positivity during the course of the disease, persistent pre- and post-stop responses to nucleoside analogues, probable HBV reactivation, and risk of HCC development or recurrence.